BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16257613)

  • 1. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.
    Callejon DR; Franceschini SA; Montes MB; Toloi MR
    Maturitas; 2005; 52(3-4):249-55. PubMed ID: 16257613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
    Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.
    Thromb Haemost; 1996 Mar; 75(3):476-80. PubMed ID: 8701411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women.
    Martínez C; Basurto L; Zárate A; Saucedo R; Gaminio E; Collazo J
    Maturitas; 2005 Jan; 50(1):39-43. PubMed ID: 15590212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].
    Ciepłuch R; Czestochowska E
    Pol Tyg Lek; 1995 Sep; 50(36-39):13-5. PubMed ID: 8650021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antiretroviral therapy on hemostasis in Brazilian pregnant women with HIV infection.
    de Andrade CM; Duarte G; Quintana SM; Montes MB; Toloi MR
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):769-74. PubMed ID: 17982318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial.
    Ricci G; Cerneca F; Simeone R; Pozzobon C; Guarnieri S; Sartore A; Pregazzi R; Guaschino S
    Hum Reprod; 2004 Apr; 19(4):838-48. PubMed ID: 15016779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
    Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women.
    Sumino H; Ichikawa S; Sawada Y; Sakamoto H; Kumakura H; Takayama Y; Sakamaki T; Kurabayashi M
    Thromb Res; 2005; 115(5):359-66. PubMed ID: 15733968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.
    Koh KK; Mincemoyer R; Bui MN; Csako G; Pucino F; Guetta V; Waclawiw M; Cannon RO
    N Engl J Med; 1997 Mar; 336(10):683-90. PubMed ID: 9041098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
    Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study.
    Fait T; Vrablik M; Zizka Z; Kostirova M
    Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
    Lindoff C; Peterson F; Lecander I; Martinsson G; Astedt B
    Maturitas; 1996 May; 24(1-2):43-50. PubMed ID: 8794433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
    Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3071-8. PubMed ID: 9409295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women.
    Bonduki CE; Lourenço DM; Baracat E; Haidar M; Noguti MA; da Motta EL; Lima GR
    Acta Obstet Gynecol Scand; 1998 Mar; 77(3):330-3. PubMed ID: 9539282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
    Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
    Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.